Market Overview

UPDATE: ISI Group Upgrades Bruker Corporation to Buy, Raises PT

Related BRKR
Bruker Corp Has 'Great Story,' But It's Not Time To Jump In Yet
Bruker Introduces MALDI Tissuetyper Solution With New High Speed RapifleX MALDI-TOF MS System For Anatomical Pathology Research

In a report published Monday, ISI Group upgraded its rating on Bruker Corporation (NASDAQ: BRKR) to Buy, and raised its price target from $15.00 to $19.00.

ISI Group noted, “We are upgrading shares of Bruker in conjunction with ISI's transition to an absolute return rating system and are raising our price target from $15.00 to $19.00. Under the leadership of new CFO Wagner, we expect cost containment and streamlining efforts to benefit operating margins and free cash flow over the medium term. EPS power should be further buffeted by continued strong new product momentum that should also translate into organic revenue growth upside. Ultimately, we expect these tailwinds to outweigh any potential drag from funding challenges in the academic channel, and look for improved macro conditions to be a demand buffer for the industrial and applied markets.”

Bruker Corporation closed on Friday at $15.98.

Latest Ratings for BRKR

Jan 2016Cantor FitzgeraldUpgradesHoldBuy
Jan 2016Deutsche BankInitiates Coverage onHold
Jan 2016Avondale PartnersInitiates Coverage onMarket Perform

View More Analyst Ratings for BRKR
View the Latest Analyst Ratings

Posted-In: ISI GroupAnalyst Color Upgrades Analyst Ratings


Related Articles (BRKR)

View Comments and Join the Discussion!

Get Benzinga's Newsletters